{"id":11631,"date":"2022-12-02T14:46:00","date_gmt":"2022-12-02T14:46:00","guid":{"rendered":"https:\/\/www.breakthrought1d.org\/greaternewengland\/?p=11631"},"modified":"2025-10-03T11:43:24","modified_gmt":"2025-10-03T11:43:24","slug":"massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions","status":"publish","type":"post","link":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/","title":{"rendered":"Massachusetts Medicaid (MassHealth) now covers Gvoke\u00ae with no restrictions"},"content":{"rendered":"

\"\"<\/a><\/p>\n

As of 10\/31\/2022, Massachusetts Medicaid lives have unrestricted access to Gvoke\u00ae<\/a> (glucagon injection)- ready-to-use glucagon for the treatment of severe hypoglycemia for adults and children with diabetes ages 2 and above.1 \u00a0<\/sup>The ADA Standards of Care recommends prescribing glucagon for all individuals at increased risk of level 2 or level 3 hypoglycemia so it\u2019s available if needed.2<\/sup> This coverage will allow even more patients on insulin to have access to a ready-to-use glucagon to treat severe hypoglycemia.<\/p>\n

INDICATION AND IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n

GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.<\/p>\n

IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n

Contraindications<\/strong>
\nGVOKE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure, insulinoma because of the risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.<\/p>\n

Warnings and Precautions<\/strong>
\nGVOKE is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.<\/p>\n

In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, GVOKE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously.
\nAllergic reactions have been reported with glucagon. These include generalized rash, and in some cases, anaphylactic shock with breathing difficulties and hypotension. GVOKE is contraindicated in patients with a prior hypersensitivity reaction.<\/p>\n

GVOKE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia, may not have adequate levels of hepatic glycogen for GVOKE administration to be effective. Patients with these conditions should be treated with glucose.<\/p>\n

Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas (glucagon-producing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported postmarketing following continuous glucagon infusion. NME lesions may affect the face, groin, perineum and legs or be more widespread. In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks.<\/p>\n

Adverse Reactions<\/strong>
\nMost common (\u22655%) adverse reactions associated with GVOKE are nausea, vomiting, injection site edema (raised 1 mm or greater), and hypoglycemia.<\/p>\n

Drug Interactions<\/strong>
\nPatients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE. In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin.<\/p>\n

Please see Full Prescribing Information<\/strong> here<\/a>.<\/p>\n

References: <\/strong><\/p>\n

    \n
  1. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc; 2021. 2.<\/strong> American Diabetes Association. Standards of Medical Care in Diabetes\u20132021 abridged for primary care providers. Clinical Diabetes. 2021;39(1):14-43. https:\/\/doi.org\/10.2337\/cd21-as01<\/a>.<\/li>\n<\/ol>\n
    \n

    Breakthrough T1D produces this content to provide information to our supporters about their potential options for managing their T1D and not as an endorsement of products. Editorial control rests solely with Breakthrough T1D.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    As of 10\/31\/2022, Massachusetts Medicaid lives have unrestricted access to Gvoke\u00ae (glucagon injection)- ready-to-use glucagon for the treatment of severe hypoglycemia for adults and children with diabetes ages 2 and above.1 \u00a0The ADA Standards of Care recommends prescribing glucagon for…<\/p>\n","protected":false},"author":1317,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ep_exclude_from_search":false,"publish_on_app_meta":"True","iawp_total_views":1,"footnotes":"","bt1d_storytelling_post":false,"bt1d_storytelling_more_posts":[]},"topics":[20],"class_list":["post-11631","post","type-post","status-publish","format-standard","hentry","jdrf_topic-general"],"acf":[],"yoast_head":"\nMassachusetts Medicaid (MassHealth) now covers Gvoke\u00ae with no restrictions - Greater New England Chapter<\/title>\n<meta name=\"description\" content=\"Breakthrough T1D covers Massachusetts Medicaid (MassHealth), which now covers Gvoke with no restrictions. Learn more about this important development in type 1 diabetes treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Massachusetts Medicaid (MassHealth) now covers Gvoke\u00ae with no restrictions - Greater New England Chapter\" \/>\n<meta property=\"og:description\" content=\"Breakthrough T1D covers Massachusetts Medicaid (MassHealth), which now covers Gvoke with no restrictions. Learn more about this important development in type 1 diabetes treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater New England Chapter\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/breakthrought1dHQ\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-02T14:46:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-03T11:43:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.breakthrought1d.org\/easternma\/wp-content\/uploads\/sites\/131\/2022\/12\/Gvoke.png\" \/>\n<meta name=\"author\" content=\"Breakthrough T1D Author\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:site\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Breakthrough T1D Author\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/\"},\"author\":{\"name\":\"Breakthrough T1D Author\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6\"},\"headline\":\"Massachusetts Medicaid (MassHealth) now covers Gvoke\u00ae with no restrictions\",\"datePublished\":\"2022-12-02T14:46:00+00:00\",\"dateModified\":\"2025-10-03T11:43:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/\"},\"wordCount\":578,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.breakthrought1d.org\/easternma\/wp-content\/uploads\/sites\/131\/2022\/12\/Gvoke.png\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/\",\"url\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/\",\"name\":\"Massachusetts Medicaid (MassHealth) now covers Gvoke\u00ae with no restrictions - Greater New England Chapter\",\"isPartOf\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.breakthrought1d.org\/easternma\/wp-content\/uploads\/sites\/131\/2022\/12\/Gvoke.png\",\"datePublished\":\"2022-12-02T14:46:00+00:00\",\"dateModified\":\"2025-10-03T11:43:24+00:00\",\"description\":\"Breakthrough T1D covers Massachusetts Medicaid (MassHealth), which now covers Gvoke with no restrictions. Learn more about this important development in type 1 diabetes treatment.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#primaryimage\",\"url\":\"https:\/\/www.breakthrought1d.org\/easternma\/wp-content\/uploads\/sites\/131\/2022\/12\/Gvoke.png\",\"contentUrl\":\"https:\/\/www.breakthrought1d.org\/easternma\/wp-content\/uploads\/sites\/131\/2022\/12\/Gvoke.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Massachusetts Medicaid (MassHealth) now covers Gvoke\u00ae with no restrictions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/#website\",\"url\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/\",\"name\":\"Greater New England Chapter\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png\",\"contentUrl\":\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png\",\"width\":400,\"height\":400,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/breakthrought1dHQ\",\"https:\/\/x.com\/breakthrought1d\",\"https:\/\/www.youtube.com\/@breakthrought1d\",\"https:\/\/www.instagram.com\/breakthrought1d\/\",\"https:\/\/www.tiktok.com\/@breakthrought1dhq\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.breakthrought1d.org\/greaternewengland\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6\",\"name\":\"Breakthrough T1D Author\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g\",\"caption\":\"Breakthrough T1D Author\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Massachusetts Medicaid (MassHealth) now covers Gvoke\u00ae with no restrictions - Greater New England Chapter","description":"Breakthrough T1D covers Massachusetts Medicaid (MassHealth), which now covers Gvoke with no restrictions. Learn more about this important development in type 1 diabetes treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/","og_locale":"en_US","og_type":"article","og_title":"Massachusetts Medicaid (MassHealth) now covers Gvoke\u00ae with no restrictions - Greater New England Chapter","og_description":"Breakthrough T1D covers Massachusetts Medicaid (MassHealth), which now covers Gvoke with no restrictions. Learn more about this important development in type 1 diabetes treatment.","og_url":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/","og_site_name":"Greater New England Chapter","article_publisher":"https:\/\/www.facebook.com\/breakthrought1dHQ","article_published_time":"2022-12-02T14:46:00+00:00","article_modified_time":"2025-10-03T11:43:24+00:00","og_image":[{"url":"https:\/\/www.breakthrought1d.org\/easternma\/wp-content\/uploads\/sites\/131\/2022\/12\/Gvoke.png","type":"","width":"","height":""}],"author":"Breakthrough T1D Author","twitter_card":"summary_large_image","twitter_creator":"@breakthrought1d","twitter_site":"@breakthrought1d","twitter_misc":{"Written by":"Breakthrough T1D Author","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#article","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/"},"author":{"name":"Breakthrough T1D Author","@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6"},"headline":"Massachusetts Medicaid (MassHealth) now covers Gvoke\u00ae with no restrictions","datePublished":"2022-12-02T14:46:00+00:00","dateModified":"2025-10-03T11:43:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/"},"wordCount":578,"commentCount":0,"publisher":{"@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/#organization"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.breakthrought1d.org\/easternma\/wp-content\/uploads\/sites\/131\/2022\/12\/Gvoke.png","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/","url":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/","name":"Massachusetts Medicaid (MassHealth) now covers Gvoke\u00ae with no restrictions - Greater New England Chapter","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#primaryimage"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.breakthrought1d.org\/easternma\/wp-content\/uploads\/sites\/131\/2022\/12\/Gvoke.png","datePublished":"2022-12-02T14:46:00+00:00","dateModified":"2025-10-03T11:43:24+00:00","description":"Breakthrough T1D covers Massachusetts Medicaid (MassHealth), which now covers Gvoke with no restrictions. Learn more about this important development in type 1 diabetes treatment.","breadcrumb":{"@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#primaryimage","url":"https:\/\/www.breakthrought1d.org\/easternma\/wp-content\/uploads\/sites\/131\/2022\/12\/Gvoke.png","contentUrl":"https:\/\/www.breakthrought1d.org\/easternma\/wp-content\/uploads\/sites\/131\/2022\/12\/Gvoke.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/2022\/12\/02\/massachusetts-medicaid-masshealth-now-covers-gvoke-with-no-restrictions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.breakthrought1d.org\/greaternewengland\/"},{"@type":"ListItem","position":2,"name":"Massachusetts Medicaid (MassHealth) now covers Gvoke\u00ae with no restrictions"}]},{"@type":"WebSite","@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/#website","url":"https:\/\/www.breakthrought1d.org\/greaternewengland\/","name":"Greater New England Chapter","description":"","publisher":{"@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.breakthrought1d.org\/greaternewengland\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/#organization","name":"Breakthrough T1D","url":"https:\/\/www.breakthrought1d.org\/greaternewengland\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/#\/schema\/logo\/image\/","url":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","contentUrl":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","width":400,"height":400,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/breakthrought1dHQ","https:\/\/x.com\/breakthrought1d","https:\/\/www.youtube.com\/@breakthrought1d","https:\/\/www.instagram.com\/breakthrought1d\/","https:\/\/www.tiktok.com\/@breakthrought1dhq"]},{"@type":"Person","@id":"https:\/\/www.breakthrought1d.org\/greaternewengland\/#\/schema\/person\/d91bebaf8f6259d18f7a0d24d101e6e6","name":"Breakthrough T1D Author","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/671a28dc8d852432a8ab73f6c4aa3fa4daaf67bf2bda182c96c6bc7c78461c21?s=96&d=mm&r=g","caption":"Breakthrough T1D Author"}}]}},"_links":{"self":[{"href":"https:\/\/www.breakthrought1d.org\/greaternewengland\/wp-json\/wp\/v2\/posts\/11631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.breakthrought1d.org\/greaternewengland\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.breakthrought1d.org\/greaternewengland\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternewengland\/wp-json\/wp\/v2\/users\/1317"}],"replies":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternewengland\/wp-json\/wp\/v2\/comments?post=11631"}],"version-history":[{"count":0,"href":"https:\/\/www.breakthrought1d.org\/greaternewengland\/wp-json\/wp\/v2\/posts\/11631\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.breakthrought1d.org\/greaternewengland\/wp-json\/wp\/v2\/media?parent=11631"}],"wp:term":[{"taxonomy":"jdrf_topic","embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/greaternewengland\/wp-json\/wp\/v2\/topics?post=11631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}